Listing paves way for Lyxumia's Japan launch
This article was originally published in Scrip
Executive Summary
A recent price listing has set the stage for the launch in Japan of Sanofi's Lyxumia (lixisenatide), marking the first availability in this market of a GLP-1 agonist approved for use in combination with basal insulin therapy for the treatment of type 2 diabetes.